Home Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
 

Keywords :   


Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

2015-10-01 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrixs oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of form phase cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.11JELEEBOX
26.11
26.11222CB
26.11BOSS ( ) BB-1X Bass Driver
26.1112010 re0827-141
26.11
26.11 2021 EDITION
26.11DVD
More »